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Abstract
Background: Despite recent progress, therapy for metastatic clear cell renal cell carcinoma (CCRCC) is still inadequate.
Dysregulated Notch signaling in CCRCC contributes to tumor growth, but the full spectrum of downstream processes
regulated by Notch in this tumor form is unknown.
Methodology/Principal Findings: We show that inhibition of endogenous Notch signaling modulates TGF-b dependent
gene regulation in CCRCC cells. Analysis of gene expression data representing 176 CCRCCs showed that elevated TGF-b
pathway activity correlated significantly with shortened disease specific survival (log-rank test, p=0.006) and patients with
metastatic disease showed a significantly elevated TGF-b signaling activity (two-sided Student’s t-test, p=0.044). Inhibition
of Notch signaling led to attenuation of both basal and TGF-b1 induced TGF-b signaling in CCRCC cells, including an
extensive set of genes known to be involved in migration and invasion. Functional analyses revealed that Notch inhibition
decreased the migratory and invasive capacity of CCRCC cells.
Conclusion: An extensive cross-talk between the Notch and TGF-b signaling cascades is present in CCRCC and the
functional properties of these two pathways are associated with the aggressiveness of this disease.
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Introduction
Clear cell renal cell carcinoma (CCRCC) is the most common
malignancy of the kidney [1]. About a quarter of the CCRCC
patients have metastatic disease at the time of diagnosis and
eventually one-third of the patients presented with localized
tumors at diagnosis relapse. Despite recent advances using multi-
kinase inhibitors, disseminated CCRCC remains inherently
treatment resistant [2]. Consequently, studies leading to a better
understanding of the factors that determines the metastatic
phenotype of CCRCC are warranted [3]. The tumor suppressor
gene VHL is lost in approximately 80% of all CCRCCs and
represents a hallmark feature of CCRCC, but additional
oncogenic events are required for both tumor formation and
progression [4].
Notch signaling is an evolutionarily conserved signaling
pathway of fundamental importance during development and
post-natal life, regulating cell fate decisions, proliferation and
survival. Dysregulated Notch signaling has been implicated in a
wide variety of pathological conditions, including cancer [5].
Ligand (Jagged and Delta-like families) binding leads to two
proteolytic cleavages of the receptors, the latter being dependent
on the c-secretase complex. Upon cleavage, the intracellular
domain of the Notch receptor (icNotch) translocates to the nucleus
where it converts the transcriptional repressor CSL to an activator
[6]. Small molecule inhibitors that are capable of inhibiting Notch
activation by targeting the c-secretase complex are being tested for
treatment of tumor types characterized by elevated Notch
signaling, such as breast cancer and T-ALL [7]. In a recent study,
we showed that Notch signaling components were elevated in
primary CCRCC specimens compared to normal kidney and
inhibition of Notch signaling attenuated growth of CCRCC cells,
both in vitro and in vivo [8]. Thus, we have postulated that Notch
signaling might represent a novel, clinically targetable oncogenic
pathway in this pathological context.
The TGF-b pathway has a dual role in tumorigenesis: the
growth inhibiting function at early stages of tumor formation is
breached during tumor progression and at later stages TGF-b
signaling can promote cell migration and invasion [9]. TGF-b
elicits its cellular responses by binding to TGF-b type I and type II
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phosphorylate intracellular messengers SMAD2 and SMAD3,
which in complex with SMAD4 transcriptionally induce or repress
a diverse array of genes. In CCRCC, loss of TGFBR2 has been
reported, which has been associated with tumor progression and
also suggested to be the mechanism responsible for the escape
from TGF-b-mediated growth repression [10,11,12,13]. However,
there are also studies showing that loss of TGFBR2 expression is
associated with improved CCRCC patient survival and that the
TGF-b cascade promotes CCRCC bone metastasis in vivo [14,15].
Here we sought to identify downstream targets of the Notch
pathway in CCRCC by employing transcriptome analyses of c-
secretase treated CCRCC cells. Our data indicate that inhibition
of Notch signaling attenuates the TGF-b transcriptional output
and that elevated TGF-b signaling activity in primary CCRCC is
associated with decreased survival. This study thus provides
additional rationale for targeting the Notch pathway for treatment
of CCRCC.
Results
Notch inhibition in CCRCC cells affects TGF-b gene
signatures
Our previous work established that active Notch signaling is an
inherent property of CCRCC cells [8]. To further confirm this
observation, we performed Western blot experiments on extracts
from 786-O and SKRC-10 cells using an antibody that specifically
recognizes activated Notch1 (icNotch1). As anticipated, icNotch1
was detected in control treated cells whereas treatment with the c-
secretase inhibitor DAPT completely abolished the levels of
icNotch1 in both cell lines (Figure 1A). We next analyzed global
gene expression changes following Notch inhibition using micro-
arrays. The Notch target genes HES1 and IL7R [8,16] were both
strongly downregulated in both 786-O and SKRC-10 cells
(Table 1), thus validating our approach.
Interestingly, five of the most downregulated genes common to
both cell lines are known TGF-b target genes [9,17,18] (Table 1).
Wenextasked whetherthiscross talkcould bestatisticallyverified in
our data using gene set enrichment analysis (GSEA) [19]. DAPT
modulatedgeneexpressionintheSKRC-10microarrayexperiment
were ranked based on Rank product analysis FDR [20]. As
exemplified in Figure 1B, GSEA showed significant enrichment of
several genes related to TGF-b induced transcription among the
DAPT down regulated genes [21]. In a direct comparison we noted
a consistent repression of several well-described TGF-b induced
genes in DAPT treated samples (Figure 1C) [9,17,18]. Likewise,
some previously characterized TGF-b downregulated genes (e.g.
CEPBD, CITED2, SPRY2,a n dRIN1) were significantly upregulated
upon c-secretase inhibition (Figure 1D). The downregulation of
HES1 and the TGF-b target genes SERPINE1 and SKIL were
confirmed using Quantitative real-time PCR (Q-PCR) in both 786-
O and SKRC-10 cells (Figure 1E).
Overall, these results show that Notch inhibition not only affects
prototypical Notch target genes but also modulates TGF-b
dependent gene regulation in CCRCC cells.
Association between TGF-b pathway activity and
prognosis in CCRCC patients
We next investigated the clinical relevance of TGF-b signaling
in primary CCRCCs. It is known that TGF-b signaling acts in a
highly tissue-specific manner. We therefore extracted a core set of
TGF-b target genes relevant for CCRCC cells, by analyzing
published TGF-b gene expression signatures derived from
hepatocytes, breast cancer and fibroblasts using GSEA
[21,22,23]. We selected those genes from each of the TGF-b
gene sets that contributed to the significant enrichment in the data
from DAPT treated SKRC-10 cells, i.e. the leading edge subset
from each GSEA analysis [19]. We thereby defined a core TGF-b
gene expression signature of 145 genes, representing documented
TGF-b target genes also affected in c-secretase inhibited CCRCC
cells (Table S1). This gene set was used to query a published gene
expression data set of 176 CCRCCs [24] for correlations to
survival. For each sample a specific TGF-b activity score was
calculated based on the 145-gene signature. Survival analysis using
Kaplan-Meier plots revealed that high TGF-b pathway activity
score was significantly associated with a worse disease-specific
survival (log-rank, p=0.006; Figure 2A). Interestingly, using AJCC
stage grouping, grade and performance status as covariates the
TGF-b pathway activity also provided independent prognostic
information when treated as a continuous variable in a
multivariate Cox regression model (p=0.004, HR=4.04, 95%
confidence interval (CI)=1.55–10.53) (Table S2). Together, these
analyses show that the TGF-b pathway is active and correlates to
poor outcome in primary CCRCCs.
We next surveyed a collection of primary CCRCC specimens
using an antibody directed against phosphorylated SMAD2
(pSMAD2), generally considered as a specific assessment of
TGF-b signaling activity. We validated the anti-pSMAD2
antibody by staining paraffin-embedded 786-O cells that had
been cultured in the presence or absence of the potent TGFBR1
inhibitor SB431542 [25] (Figure 2B). The primary CCRCCs
generally showed strong nuclear pSMAD2 staining (Figure 2C),
indicating that activation of the TGF-b cascade is a persistent
feature of CCRCC.
Characterization of the TGF-b responsiveness in CCRCC
cells
Since the published data regarding the role of the TGF-b
receptors in CCRCC are conflicting, we analyzed the prognostic
impact of these receptors in the data set from 176 CCRCCs
(Figure S1). Our analysis revealed a significant association between
high expression of TGFBR1 and worse disease-specific survival
(log-rank, p=0.030). Low expression of TGFBR3 was also
associated with worse disease-specific survival (log-rank,
p=0.010). No significant association between survival and
expression of TGFBR2 could be detected.
Studies using CCRCC cells (including the 786-O cell line)
suggested that intracellular TGF-b signaling is lost due to absence
of the TGFBR2 receptor [10,11]. Baseline level of pSMAD2 could
however be detected in 786-O cells using immunohistochemistry
(Figure 2B). To further confirm the existence of a cell autonomous
TGF-b signaling pathway in CCRCC cells, we analyzed the
expression of TGFBR1 and TGFBR2 using Western blotting.
Both 786-O and SKRC-10 cells expressed appreciable levels of the
two receptors (Figure 3A). We also monitored the level of
pSMAD2 in the presence or absence of exogenously added
TGF-b1 by Western blotting. We noted a baseline activity of
pSMAD2 in unstimulated 786-O and SKRC-10 cells. The level of
pSMAD2 in TGF-b1 treated cells remained higher compared to
control cells during the entire experiment in both cell lines
(Figure 3B and 3C). Treatment with SB431542 led to a complete
loss of the pSMAD2 signal (Figure 3D). Previous reports have
indicated that the expression of TGF-b1 is elevated in CCRCC
due to the loss of pVHL [10,26], which are results compatible with
our observations of pSMAD2 expression in primary CCRCCs and
baseline expression of pSMAD2 in unstimulated CCRCC cells. In
order to assess TGF-b1 production in 786-O and SKRC-10 cells,
we employed an ELISA assay. After 48 hours, TGF-b1 could be
Notch and TGF-b Signaling in RCC
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When 786-O and SKRC-10 cells were transfected with a plasmid
containing a SMAD regulated luciferase reporter ((CAGA)12-Luc), a
dose-dependent increase of the luciferase reporter was detected
upon TGF-b1 stimulation (Figure 3F and 3G, respectively). This
induction was dependent of TGFBR1 activation, since treatment
with SB431542 abrogated both TGF-b1 induced and basal
reporter gene activity (Figure 3F–H). Q-PCR experiments showed
that the expression of the TGF-b responsive genes JUNB and
SERPINE1 were significantly induced upon treatment with TGF-
b1 and suppressed below baseline when the cells were treated with
SB431542 alone or in combination with TGF-b1 (Figure 3I).
Based on these experiments, we conclude that the TGF-b
signaling pathway is functional in the two investigated CCRCC
cell lines and that the basal activity might be a consequence of
endogenous TGF-b1 production.
Figure 1. Notch inhibition in CCRCC cells attenuates TGF-b signaling. (A) Western blot analysis of icNotch1 in 786-O and SKRC-10 cells
treated for 24 h with DAPT (+) or vehicle control (2). Cell extracts were separated by SDS-PAGE and after transfer the membrane was probed with an
anti-cleaved Notch1 antibody. The blot was reprobed with an anti-ACTIN antibody to ensure equal loading. (B) GSEA of a TGF-b upregulated gene set
classified as upregulated by TGF-b1 treatment of skin fibroblasts at 1–4 h in the SKRC-10 microarray data. Isolated and purified RNA from SKRC-10
cells, treated with DAPT or vehicle control in 1% FCS supplemented media for 24 h, was used in oligomer microarray experiments. Genes in the SKRC-
10 data list were ranked for downregulation upon DAPT treatment by measure of rank product analysis FDR. Gene sets with a q-value below 0.25
were considered significantly enriched. Genes upregulated by TGF-b1 from the gene set were significantly enriched in the list ranked by
downregulated by DAPT (NES=1.75, q=0.09). (C) Gene expression analysis of indicated genes reported to be activated in response to TGF-b in DAPT
or vehicle control (c) treated SKRC-10 cells. Cells were treated as indicated in (B). Data represents mean log2 ratios+95% confidence intervals of three
separate experiments. (D) Gene expression analysis of indicated genes reported to be repressed in response to TGF-b in DAPT or vehicle control (c)
treated SKRC-10 cells. Cells were treated as indicated in (B). Data represents mean log2 ratios+95% confidence intervals of three separate
experiments. (E) Notch inhibition in CCRCC cells decreases the mRNA expression of the Notch primary target HES1 and the TGF-b target genes
SERPINE1 and SKIL. Q-PCR analyses of HES1, SKIL and SERPINE1 mRNA levels in 786-O or SKRC-10 cells treated for 24 h with DAPT or vehicle control (c).
mRNA levels were normalized to SDHA, YWHAZ and UBC expression and data represents mean+95% confidence intervals of three separate
experiments. ***, ** and * indicates statistical significant changes (two-sided Student’s t-test, p,0.001, p,0.01 and p,0.05 respectively).
doi:10.1371/journal.pone.0023057.g001
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We next wanted to characterize the effects of Notch inhibition
on TGF-b signaling. 786-O cells showed a modest but consistent
decrease of basal pSMAD2 levels upon treatment with DAPT at
all time-points analyzed, while the SMAD2 levels were unaffected
all through the time course of the experiment (Figure 4A). Similar
results were obtained when analyzing the SK-RC10 cell line (data
not shown). Also, when transfecting the cells with siRNA against
Notch1 a down-regulation of pSMAD2 levels could be detected
(Figure 4B). Notch inhibition also decreased phosphorylation of
SMAD2 in cells stimulated with TGF-b1 (Figure 4C).
We next wanted to analyze whether the suppressive effect on
TGF-b pathway activity by Notch inhibition could be reversed by
constitutively active, c-secretase insensitive Notch signaling. For
this purpose, we co-transfected 786-O cells with the (CAGA)12
luiferase reporter together with an icNotch1 expression vector and
treated the cells with DAPT. As shown in figure 4E, expression of
icNotch1 led to a significant increase in reporter activity compared
to vector control. In the presence of DAPT, expression of
icNotch1 led to a partial but significant reversal of the DAPT
induced suppression of reporter activity (Figure 4E). We further
corroborated the diminished basal and TGF-b1 induced TGF-b
activity upon treatment with DAPT using the (CAGA)12 reporter
(Figure 4D, 4F and 4G). Modulation of Notch signaling also
affected TGF-b responsive genes (JUNB and SERPINE1) in the
presence of TGF-b1 (Figure 4H).
Altogether, our data indicate that inhibition of Notch signaling
downregulates TGF-b signaling in CCRCC cells.
Notch inhibition perturbs the migratory capacity of
CCRCC cells
The dual role of TGF-b signaling in cancer is well established,
with a cytostatic effect in the early stages, which can be subdued to
a metastatic promoting program at the later stages of tumor
progression [17]. We noted however very modest effects on the
cytostatic TGF-b transcripts [9] in DAPT treated SKRC-10 cells
(Figure S2A). Consistent with this observation and with a previous
report [10], thymidine incorporation assays confirmed that the
growth capacity of CCRCC cells was not decreased by treatment
with TGF-b1 for up to 72 h (Figure 5A). In case of the SKRC-10
cells there was even a modest but significant increase in growth at
72 h of treatment with TGF-b1.
Our microarray experiments indicated that genes regulating
migration and/or invasion were downregulated (Figure S2B).
Most of these genes are also directly regulated by TGF-b signaling
and have been associated with aggressive and invasive cancer [17].
This observation suggested that Notch inhibition perturbs the
migratory and/or invasive capacity of CCRCC cells. We
functionally verified this using Boyden chamber assays and noted
a significant decrease in migration when CCRCC cells were
treated with DAPT (Figure 5B) or upon Notch1 knockdown
(Figure 5C) compared to control treated cells. Also, treatment with
the TGF-b inhibitor SB431542 led to a significant decrease in
migration of SK-RC10 cells and when combining SB431542 and
DAPT treatments, no further decrease in migration was noted
(Figure 5D). Addition of exogenous TGF-b1 further stimulated the
migratory capacity and this effect could be attenuated by Notch
inhibition (Figure 5E). Furthermore, Notch inhibition led to a
pronounced and significant decrease in invasion in both cell lines
tested when compared with vehicle control (Figure 5F). To verify
the clinical significance of these results, we assessed TGF-b
signaling activity based on our 145-gene TGF-b signature in a
previously published microarray study [27]. CCRCCs from
patients with either metastatic disease at diagnosis or that later
developed metastasis (n=13) showed a significantly elevated TGF-
b signaling activity as compared to tumors from patients with a
localized disease and with no documented metastases during
follow-up (n=9) (two-sided Student’s t-test, p=0.044, Figure 5G).
Thus, dysregulated Notch signaling might contribute to
CCRCC aggressiveness at least in part by modulating TGF-b
signaling activity.
Discussion
It has been shown that loss of VHL, which is the key oncogenic
event in CCRCC, leads to elevated expression of TGF-b1 [10].
Interestingly, elevated levels of TGF-b1 in serum from CCRCC
patients are correlated with unfavorable outcome of the disease
[26,28,29]. Hence, the tumor microenvironment in CCRCC is
rich in TGF-b1. These observations therefore suggest that
CCRCC cells might have acquired the capacity to evade the
cytostatic effects imposed by the presence of TGF-b1. It has been
postulated that structural alterations of TGF-b pathway compo-
nents, such as mutations of TGFBR2 render tumor cells insensitive
to TGF-b cytostatic effects [17]. In CCRCC there are conflicting
reports on such alterations and there is an apparent lack of
functional analyses of signaling activity, e.g. assessment of
Table 1. Top downregulated genes common to both 786-O
and SKRC-10 cells upon c-secretase inhibition when
compared to vehicle treatment for 24 hours as evaluated
from microarray data.
786-O SKRC-10
Gene name Mean ratio Z Mean ratio Z
HES1 21.44 24.80 22.98 28.54
IL7R 20.77 22.57 21.74 25.02
LOC284422 22.10 26.96 21.48 24.30
CXCL12 21.32 24.38 21.31 23.80
CXCR7 21.03 23.44 21.30 23.78
SNF1LK 20.71 22.37 21.29 23.74
GPR56 20.82 22.73 21.25 23.63
MAOB 21.15 23.84 21.22 23.55
SERPINE1 20.96 23.19 21.21 23.53
SEMA3F 21.11 23.69 21.19 23.47
KRTAP9-4 21.07 23.59 21.16 23.38
LPHN1 21.37 24.58 21.14 23.34
HSF2BP 20.71 22.38 21.13 23.29
CLTCL1 21.05 23.49 21.07 23.13
MN1 20.93 23.10 21.07 23.13
GALNT2 20.82 22.76 20.91 22.68
LRP4 20.71 22.40 20.90 22.63
CHAC1 20.70 22.34 20.84 22.47
FAM20C 20.63 22.13 20.80 22.35
INHBA 21.36 24.54 20.79 22.32
SR-A1 20.61 22.06 20.74 22.18
SKIL 20.68 22.27 20.69 22.05
Genes in bold represents previously described TGF-b signaling target genes.
Data represents mean log2 ratios (DAPT/DMSO) and Z-scores of three separate
experiments. The genes are sorted according to the Z-scores of SKRC-10.
doi:10.1371/journal.pone.0023057.t001
Notch and TGF-b Signaling in RCC
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23057Notch and TGF-b Signaling in RCC
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23057pSMAD2 levels. Experimental in vitro and in vivo studies have
indicated that TGBR3 have antitumoral effects in CCRCC cells
independent of TGF-b1 and canonical TGFBR1/TGFBR2/
SMAD signaling [11]. Our data showing that low TGFBR3
expression in primary CCRCC is significantly associated with
worse disease-specific survival is thus adding further support for
this notion. Loss of TGFBR2 has been linked to CCRCC
progression [10,11,12,13], whilst another investigation showed
that loss of TGFBR2 improve CCRCC patient survival [15]. In
favor of the latter study, the TGF-b cascade has been shown to
promote CCRCC bone metastasis in vivo [14]. It is noteworthy that
Ananth et al, concluded that the 786-O cells lacks a working TGF-
b signaling pathway due to the absence of TGFBR2 expression
[10]. In contrast, our functional assessment of the pathway in 786-
O cells clearly shows that the pathway remains intact. In normal
renal cells, TGF-b1 elicits an antimitogenic response and triggers
epithelial-to-mesenchymal transition [18,30,31,32,33]. While our
data indicate that CCRCC cells are insensitive to TGF-b-induced
growth inhibition, the cells retain an operational TGF-b pathway
that directs pro-migratory and pro-metastatic functions. Consis-
tent with the experimental data, we found evidence of SMAD2
activation in clinical specimens and an association between TGF-b
signaling activity, disease-specific survival and metastatic progres-
sion in the analyses of primary CCRCCs. Our observation that
elevated TGFBR1 is significantly associated with worse disease-
specific survival provides further support for a pro-metastatic
function of TGF-b signaling in CCRCC. Thus, we extend
previous data and suggest a pro-oncogenic role for a hyperacti-
vated autocrine TGF-b pathway in CCRCC. This tumor-
promoting effect of pathogenic TGF-b signaling could partly be
manifested in an increased metastatic potential of the tumor cells,
but also through paracrine angiogenic and immunosuppressive
effects of TGF-b secreted by the growing tumor mass [10,34].
Different modes of cross-talk between the TGF-b and Notch
signaling pathways of both synergistic and antagonistic nature
have been reported in various cellular contexts [35,36,37,38,39,
40,41,42,43,44]. In CCRCC cells, characterized by high activity
of both pathways, Notch signaling seems superimposed on TGF-b
signaling since Notch inhibition, either by siRNA targeting Notch1
or pharmacological inhibition of Notch receptor activation, clearly
perturbs important aspects of metastasis associated TGF-b
signaling.
Since metastatic CCRCC has a particularly poor prognosis, with
a five-year survival of about 9%, it is critical to develop treatment
strategies that target the metastatic process [1]. We have recently
developed a novel c-secretase inhibition strategy, using intermittent
treatment cycles that strongly inhibited the growth of xenotrans-
planted CCRCC cells while limiting the toxicity of the intestine,
which is a major obstacle in achieving effective doses of these drugs
in humans [8]. In a recent study it was also shown that
glucocorticoids abrogate the gastrointestinal toxicity of c-secretase
inhibitors [45]. Thus, these studies provide alternative strategies to
spare the patients from the side effects of systemic Notch inhibition.
We now provide evidence that Notch inhibition also attenuates
the migratory capacity of CCRCC cells, at least in part through
modulation of TGF-b signaling. In addition, it is known that
inhibition of Notch signaling perturbs tumor angiogenesis [46].
Thus, we conclude that Notch inhibition might be a particularly
appealing approach for treatment of CCRCC, potentially curbing
several key aspects of tumor aggressiveness.
Materials and Methods
Cell culture and reagents
The 786-O (ATCC, Rockville, MD, USA) CCRCC cell line
was cultured in DMEM (Invitrogen, Stockholm, Sweden)
containing 10% fetal calf serum (FCS, Invitrogen) and supple-
mented with 1% penicillin and streptomycin (PEST, Invitrogen).
The SKRC-10 CCRCC cell line was maintained in RPMI 1640
(Invitrogen) containing 10% FCS and 1% PEST. Human
recombinant TGF-b1 was obtained from PeproTech (London,
United Kingdom). Cells were treated with 2 mM TGFBR1
inhibitor (SB431542, Sigma Aldrich, Munich, Germany), 10 mM
c-secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-ala-
nyl]-S-phenylglycine t-butyl ester) from Calbiochem (Darmstadt,
Germany) or the corresponding volume of DMSO (Sigma Aldrich)
for indicated times. All experiments were performed in reduced
serum conditions.
Microarray and data analyses
RNA from 786-O and SKRC-10 cells, treated with DAPT or
vehicle control in 1% FCS supplemented media for 24 h, was used
for gene expression microarray experiments with a 27 k cDNA
array platform (http://www.lth.se/sciblu). Array production, sam-
ple labeling, hybridization and scanning were performed essentially
as described previously [47]. In short, 5 mg of total RNA (DAPT or
vehiclecontrol) waslabeled withCy3 and hybridized against 5 mgo f
Cy5-labeled RNA from a pool representing nine untreated
CCRCC cell lines. As the effects of DAPT treatment were of
different magnitude inSKRC-10and 786-O cells,a comparative Z-
score was calculated by dividing the mean log2 ratio values for each
gene and cell line with the standard deviation of all mean log2 ratios
for each cell line. We perfomed a second round of experiments
(dubbed SKRC-10 data set), that were used for GSEA [19] and
extraction of gene expression signatures for pathway analysis. Rank
product analysis [20] was used to create ranked gene lists based on
both upregulation and downregulation. The downregulated ranked
gene lists were used for correlation analyses to known gene
signatures according to the GSEA method using the Molecular
Signatures Database (MSigDB), and additional published TGF-b
regulated gene sets [22,23].
Genes in the SKRC-10 data set contributing to a significant
enrichment of the TGF-b gene sets were thereafter used to
generate a DAPT/TGF-b specific signature. To investigate
possible clinical significance of this obtained TGF-b gene
signature, two gene expression data sets were used. The first,
which comprised 177 CCRCCs, was obtained from the Stanford
microarray database [48] and normalized as described in the
original publication [24]. Replicate reporters were merged by
gene-symbol and a presence filter was applied allowing not less
than 50% presence for each gene across arrays. The second data
set comprised 22 CCRCCs and 23 normal kidney samples [27].
Figure 2. High TGF-b signaling pathway activity is associated with decreased patient survival. (A) Kaplan-Meier curves comparing
disease-specific survival among 176 CCRCC patients divided into quartiles based on the TGF-b activity score. High TGF-b pathway activity score (76–
100%) was significantly (log-rank, p=0.006) associated with a worse disease-specific survival. (B) Immunohistochemical analyses using phospho-
specific SMAD2 (pSMAD2) antibody of control (c) or SB431542 treated 786-O cells. Sections were counterstained with hematoxylin-eosin. Original
magnification, 640. (C) pSMAD2 is expressed in vivo. Immunohistochemistry of pSMAD2 in nine CCRCC tumors, that all showed positive nuclear
staining. Sections were counterstained with hematoxylin-eosin. Original magnification, 640.
doi:10.1371/journal.pone.0023057.g002
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23057Figure 3. The TGF-b signaling pathway is functional in CCRCC cells. (A) Immunoblotting using TGFBR1 and TGFBR2 antibodies of cell lysates
from 786-O and SKRC-10 cells. (B and C) pSMAD2 and SMAD-1/2/3 protein levels in cell lysates from 786-O (B) and SKRC-10 (C) cells stimulated with
vehicle control (2) or 0.25 ng/ml TGF-b1( +) for the indicated time points. (D) Western blot analysis using pSMAD2 antibody and SMAD2 antibody, of
cell lysates from 786-O and SKRC-10 cells treated with vehicle (2) or SB431542 (+) for 4 h. (E) ELISA measurement of TGF-b1 levels in serum free
media from 786-O and SKRC-10 cells grown for 48 h. Data represents mean+95% confidence intervals of three separate experiments. (F and G) 786-O
(F) and SKRC-10 (G) cells were transfected with the SMAD regulated (CAGA)12-Luc reporter construct, treated with vehicle control (c), increasing
concentrations of TGF-b1 or 0.25 ng/ml TGF-b1 and SB431542 for 24 h and analyzed for relative luciferase activity. Data represents mean+95%
confidence intervals of three separate experiments. Data were normalized to vehicle control treated cells. (H) 786-O or SKRC-10 cells were transfected
with the (CAGA)12-Luc reporter construct, treated with vehicle control (c) or SB431542 for 24 h and analyzed for relative luciferase activity. Data
represents mean+95% confidence intervals of three separate experiments. Data were normalized to vehicle control treated cells. (I) Q-PCR analyses of
JUNB and SERPINE1 mRNA levels in SKRC-10 cells treated with vehicle control (c), SB431542 and/or 0.25 ng/ml TGF-b1 for 4 h. mRNA levels were
normalized to SDHA, YWHAZ and UBC expression and data represents mean+95% confidence intervals of three separate experiments. ***, ** and *
indicates statistical significant changes (two-sided Student’s t-test, p,0.001, p,0.01 and p,0.05 respectively).
doi:10.1371/journal.pone.0023057.g003
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23057Figure 4. Notch inhibition alters endogenous and TGF-b1 induced activation of the TGF-b signaling pathway. (A) Immunoblotting
using pSMAD2 antibody and SMAD2 antibody, of cell lysates from 786-O cells stimulated with vehicle control (2) or DAPT (+) for the indicated time
points. (B) Immunoblotting using Notch1 antibody and pSMAD2 antibody of cell lysates from 786-O and SKRC-10 cells transfected with control siRNA
(c-si) or siRNA against Notch1 (siN-1). Cells were harvested after 24 h of transfection. (C) Western blot analysis, using pSMAD2 antibody and SMAD-1/
2/3 antibody of cell lysates from 786-O and SKRC-10 cells stimulated with 0.25 ng/ml TGF-b1 and vehicle (2) or 0.25 ng/ml TGF-b1 and DAPT (+) for
4h .( D) 786-O and SKRC-10 cells transfected with the (CAGA)12-Luc reporter construct and treated with vehicle control (c) or DAPT for 24 h and
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23057Log2 expression values for each reporter were centered according
to the median expression of the normal samples and replicate
reporters were merged by gene symbol. For each sample, a TGF-b
pathway activity score was calculated as previously described [49].
Disease-specific survival (DSS) and American Joint Committee on
Cancer (AJCC) stage grouping (I, II, III or IV) were available for
176 of the 177 patients in the Zhao et al cDNA gene expression
data set [24]. Follow-up time was limited to five years. For
Kaplan-Meier analyses, patients were divided into quartiles based
on their relative TGF-b pathway activity score and interquartile
differences in survival were assayed using the log-rank test. All
statistical analyses were carried out using the R statistical
programming environment (http://www.r-project.org). Specifical-
ly, for survival analyses the Survival package was used.
Quantitative real-time PCR analyses
Q-PCR analyses, total RNA extraction and quantification of
gene expression using SYBR Green (Applied Biosystems, Foster
City, CA, USA) were done according to previously published
procedures [50]. Primer sequences are given in Table S3.
Quantification of relative mRNA levels was done using the
comparative C
t method and normalized to three endogenous
references genes (SDHA, YWHAZ and UBC) [51].
Luciferase reporter assays and siRNA transfection
For siRNA experiments, cells were transfected with control
siRNA or siRNA against Notch1 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) using Lipofectamine 2000 (Invitrogen) and
OptiMEM I Reduced Serum Medium (Invitrogen) as described
elsewhere [8].
For luciferase experiments, cells were transiently transfected
with the luciferase reporter vector (CAGA)12-Luc containing 12
CAGA SMAD binding sites [52]. phRL-TK renilla expression
vector (Promega, Madison, WI, USA) was used as a control for
transfection efficiency. The icNotch1 expression construct was
kindly provided by J.C. Aster [53]. Cells were lysed and assayed
for luciferase and renilla activities using the Dual-Luciferase
Reporter Assay System (Promega).
Western blot analyses and immunohistochemistry
Cells were lysed in RIPA buffer, separated on a SDS–PAGE gel
and blotted onto Immobilon-P (Millipore, Bedford, MA, USA) or
Hybond-C (Amersham Biosciences, Uppsala, Sweden) membranes.
The membranes were incubated with the following primary
antibodies: anti-Notch1 (Santa Cruz Biotechnology), anti-cleaved
Notch1 (Cell Signaling Technology, MA, USA), anti-phosphory-
latedSMAD2(pSMAD2,CellSignalingTechnology),anti-SMAD2
(Cell Signaling Technology), anti-SMAD-1/-2/-3 (Santa Cruz
Biotechnology), anti-TGFBR1 (Santa Cruz Biotechnology), anti-
TGFBR2 (Santa Cruz Biotechnology) or anti-ACTIN (ICN
Biomedicals, Aurora, OH, USA). HRP-conjugated secondary
antibodies were obtained from Amersham Biosciences, Dako
(Glostrup, Denmark) and Jackson ImmunoResearch Laboratories
Inc (West Grove, PA, USA). Proteins were detected by Super Signal
chemiluminescence substrate (Pierce, Rockford, IL, USA).
Tumor samples collected at the University Hospital in Umea ˚,
Sweden, including nine nephrectomy specimens were analyzed by
immunohistochemistry. The tumors were classified as CCRCCs
according to the Heidelberg classification system [54]. All tumor
samples were obtained after permission from the patients with
informed and signed consent, and the Institutional Review Board
approved the study. pSMAD2 immunoreactivity was detected using
the Dako EnVision system and the Dako TechMate 500 aspreviously
described [8]. Sections were counterstained with hematoxylin-eosin.
To evaluate antibody specificity, pSMAD2 immunoreactivity of
vehicle control treated 786-O cells or 786-O cells in which the
antigen had been eliminated by SB431542 for 24 h were performed.
TGF-b1 ELISA assay
Cells were maintained in FCS-free media for 48 h, whereafter
an ELISA was performed using the Human TGF-b1 immunoas-
say (R&D Systems Inc, Minneapolis, MN, USA) according to the
manufacturer’s description. An ELISA microplate reader (BioTek
Synergy 2, Fisher Scientific, Gothenburg, Sweden) was used to
analyze the absorbance (450 nm).
Cell proliferation assays
Cells were seeded in 1% FCS media supplemented with vehicle
control or TGF-b1 and incubated for 24, 48 or 72 h.
[
3H]thymidine (Amersham Biosciences) was then added to the
culture. Cells were harvested after 24 h of incubation. The
incorporated [
3H]thymidine was measured in a ß-liquid scintilla-
tion counter (LKB RackBeta Wallace, Turku, Finland).
Migration and invasion assays
In c–secretase inhibition experiments, cells were pretreated for
24 h with DAPT or vehicle control before initiation of the
migration assay. Cells were then seeded in FCS-free media
supplemented with DMSO, DAPT and/or TGF-b1 into Boyden
chambers (Corning, Bodenheim, Germany) with 8-mm pore size
polycarbonate membrane filters. In experiments combining
SB431542 and DAPT, SKRC-10 cells were pretreated with
2 mM SB431542 alone, in combination with 10 mM DAPT or
with vehicle control (DMSO) in 1% FCS supplemented media for
24 h. The cells were then allowed to migrate towards the lower
compartment containing 10% FCS for 4 h (786-O) or 5 h (SKRC-
10). The migrated cells were then fixed with 4% paraformalde-
hyde (Sigma Aldrich) and stained with DAPI ([49,69-diamidino-2-
phenylindole], Sigma Aldrich). The cells were thereafter counted
by microscopy at 406 magnification. Four representative fields
were counted for each filter, and each treatment condition was
assayed in triplicate and repeated three times. In siRNA
experiments, cells were transfected with control siRNA or siRNA
against Notch1 24 h preceding migration assay.
followed by measurment of relative luciferase activity. Data represents mean+95% confidence intervals of three separate experiments. Data were
normalized to vehicle control treated cells. (E) Relative luciferase activity in extracts from 786-O cells transfected with the (CAGA)12-Luc reporter
construct and vector control (Vector C) or icNotch1 expression vector followed by treatment with DAPT or vechicle control (c) for 24 h. Data
represents mean+95% confidence intervals of three separate experiments. Data were normalized to vehicle control treated and vector control
transfected cells. (F and G) 786-O (F) and SKRC-10 (G) cells were transfected with the (CAGA)12-Luc reporter construct, treated with vehicle control (c),
0.25 ng/ml TGF-b1 and vehicle control or 0.25 ng/ml TGF-b1 and DAPT for 24 h and analyzed for relative luciferase activity. Data represents
mean+95% confidence intervals of three separate experiments. Data were normalized to vehicle control treated cells. (H) Q-PCR analyses of JUNB and
SERPINE1 mRNA levels in SKRC-10 cells treated with vehicle control (c), 0.25 ng/ml TGF-b1 and vehicle (c) or 0.25 ng/ml TGF-b1 and DAPT for 4 h.
mRNA levels were normalized to SDHA, YWHAZ and UBC expression and data represents mean+95% confidence intervals of three seperate
experiments. ***, ** and * indicates statistical significant changes (two-sided Student’s t-test, p,0.001, p,0.01 and p,0.05 respectively).
doi:10.1371/journal.pone.0023057.g004
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23057Figure 5. Notch inhibition attenuates CCRCC cell migration and invasion. (A)[
3H]thymidine incorporation of 786-O and SKRC-10 cells
grown for indicated hours (h) in the presence of 1.0 ng/ml TGF-b1 or treated with vehicle control (c). Data represents mean+95% confidence intervals
of three separate experiments. Data were normalized to vehicle control treated cells. (B) Cell migration assessed by Boyden chamber assays of 786-O
and SKRC-10 cells treated with vehicle control (c) or DAPT. The cells were allowed to migrate towards the lower compartment for 4 h (786-O) or 5 h
(SKRC-10). Data represents mean+95% confidence intervals of three separate experiments. Data were normalized to vehicle control treated cells.
(C) Cell migration as determined by Boyden chamber assays of 786-O and SKRC-10 cells transfected with non-specific control (c-si) or Notch1 (siN-1)
specific siRNAs. After 24 h of transfection, cells were counted and seeded into the Boyden chamber. The cells were allowed to migrate towards the
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Matrigel
TM Matrix (BD Biosciences, Bedford, MA, USA) diluted
in FCS-free media was added on top of each Boyden chamber
membrane. The cells were seeded in FCS-free media supplemented
withDAPT orDMSO and werethen allowed to invade throughthe
Matrigel towards the lower compartment containing 10% FCS for
16 (786-O) or 21 h (SKRC-10) at 37uC. After incubation cells were
analyzed as described for the migration assay.
Statistical Analysis
Data were calculated as the mean values with 95% confidence
intervals. All statistical tests were two-sided Student’s t-test and
statistical significance was defined as p less than 0.05. For the
statistical design and analyses of gene expression microarray data
refer to ‘‘Microarray and data analyses’’ above.
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Figure S1 Disease-specific survival of 176 CCRCC
patients based on the gene expression of TGFBRs.
Kaplan-Meier plots of disease-specific survival of 176 CCRCC
patients that were divided into four groups based on the median
gene expression values of TGFBR1, TGFBR2, and TGFBR3.
Elevated TGFBR1 expression (log-rank, p=0.030) and decreased
(0–25%) TGFBR3 expression (log-rank, p=0.010) were signifi-
cantly associated with worse disease-specific survival.
(PDF)
Figure S2 Effect of c-secretase inhibition on gene
programs of interest in SKRC-10 cells. (A) Notch inhibition
does not profoundly affect the TGF-b cytostatic gene program as
assessed by gene expression analysis of SKRC-10 cells. Isolated and
purified RNA from SKRC-10 cells treated with vehicle control (c)
or DAPT in 1% FCS for 24 hours was used in oligomer microarray
experiments. Data represents mean log2 ratios of three independent
experiments+95% confidence intervals. (B) Notch inhibition leads
to downregulation of a large set of genes (* indicates previously
described TGF-b target genes) associated with cell migration and
invasion as determined by gene expression analysis of SKRC-10
cells. Isolated and purified RNA from SKRC-10 cells treated with
vehicle control (c) or DAPT in 1% FCS for 24 hours was used in
oligomer microarray experiments. Data represents mean log2 ratios
of three independent experiments+95%confidence intervals.***, **
and * indicates statistical significant changes (two-sided Student’s t-
test, p,0.001, p,0.01 and p,0.05 respectively).
(PDF)
Table S1 Core TGF-b gene expression signature of 145
genes.
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Table S2 Multivariate COX regression analyses.
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Table S3 Q-PCR primer sequences.
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